GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Jul 2026 05:22 PM
RNS
Jideytro approved in US for certain lung cancers
20 Jul 2026 07:00 AM
RNS
Bexsero 1-dose booster EMA file acceptance
17 Jul 2026 12:00 PM
RNS
Audit tender conclusion
17 Jul 2026 09:30 AM
RNS
Camlipixant phase III results update
16 Jul 2026 03:30 PM
RNS
Director/PDMR Shareholding
15 Jul 2026 01:38 PM
RNS
GSK completes acquisition of Nuvalent, Inc
14 Jul 2026 03:30 PM
RNS
Director/PDMR Shareholding
13 Jul 2026 03:30 PM
RNS
Director/PDMR Shareholding
13 Jul 2026 07:00 AM
RNS
Positive Jemperli data in dMMR/MSI-H rectal cancer
10 Jul 2026 11:58 AM
RNS
Hansoh positive Phase III results for Riz-Rez
09 Jul 2026 03:30 PM
RNS
Director/PDMR Shareholding
09 Jul 2026 10:00 AM
RNS
Directorate change
01 Jul 2026 03:00 PM
RNS
Total Voting Rights
29 Jun 2026 03:00 PM
RNS
Transaction in Own Shares
29 Jun 2026 03:00 PM
RNS
Holding(s) in Company
26 Jun 2026 03:00 PM
RNS
Holding(s) in Company
24 Jun 2026 03:30 PM
RNS
Director/PDMR Shareholding
24 Jun 2026 02:52 PM
RNS
GSK announces tender offer to acquire Nuvalent
23 Jun 2026 03:30 PM
RNS
Director/PDMR Shareholding
22 Jun 2026 03:00 PM
RNS
Transaction in Own Shares
17 Jun 2026 04:06 PM
RNS
cUTI oral antibiotic Tebipenem approved by US FDA
15 Jun 2026 03:00 PM
RNS
Transaction in Own Shares
12 Jun 2026 07:00 AM
RNS
Momelotinib orphan drug designations for VEXAS
11 Jun 2026 03:30 PM
RNS
Director/PDMR Shareholding
10 Jun 2026 03:30 PM
RNS
Director/PDMR Shareholding
09 Jun 2026 05:51 PM
RNS
Dr Hal Barron – New Directorship
09 Jun 2026 07:00 AM
RNS
GSK enters agreement to acquire Nuvalent, Inc.
08 Jun 2026 03:00 PM
RNS
Transaction in Own Shares
01 Jun 2026 03:00 PM
RNS
Transaction in Own Shares
01 Jun 2026 03:00 PM
RNS
Total Voting Rights
28 May 2026 09:30 AM
RNS
Positive Phase 3 data for bepirovirsen
27 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
26 May 2026 03:00 PM
RNS
Transaction in Own Shares
26 May 2026 03:00 PM
RNS
Admission to Trading
22 May 2026 10:30 AM
RNS
Q2 2026 Results Date Confirmed - 28 July 2026
20 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
19 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
18 May 2026 03:00 PM
RNS
Transaction in Own Shares
18 May 2026 07:00 AM
RNS
Japan MHLW approves Arexvy for adults 18-49 AIR
14 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
11 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
11 May 2026 07:05 AM
RNS
Collaboration with CTTQ for bepirovirsen
11 May 2026 07:00 AM
RNS
GSK - final tranche of share buyback programme
06 May 2026 06:22 PM
RNS
Result of AGM
05 May 2026 03:30 PM
RNS
Director/PDMR Shareholding
01 May 2026 03:00 PM
RNS
Holding(s) in Company
01 May 2026 03:00 PM
RNS
Total Voting Rights
29 Apr 2026 03:30 PM
RNS
Director/PDMR Shareholding
29 Apr 2026 07:00 AM
RNS
1st Quarter Results
28 Apr 2026 03:30 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings